Have Questions? Call Us Toll Free (877) 880-5251

Port Delivery System therapy looking for FDA approval

Roche pharmaceutical company announced the approval of their application for their Port Delivery System (PDS) as an alternative to eye injections for the treatment of wet age-related macular degeneration (AMD).

Roche is looking for marketing approval for the delivery of ranibizumab by PDS to treat wet AMD. The new device offers a continuous therapeutic dose of ranibizumab to the eye in place of regular eye injections. Approximately the size of a grain of rice, the PDS is a refillable eye implant that can be refilled every six months via a specially designed needle. 

Upon approval, the device would offer patients an alternative to the current therapy of monthly eye injections. The FDA anticipates making a decision regarding approval by October 23, 2021.

For people dealing with the dry form of macular degeneration, VisiVite offers several AREDS2 supplements that are based on the second age-related eye disease study.

Search VisiVite